Huffington Post: Healthy Living

**Slow Medicine Is the Medicine of the Future**

Kenneth R. Pelletier, PhD, MD(hc), clinical professor of medicine in the Department of Medicine and professor of public health at the University of Arizona College of Medicine – Tucson, and clinical professor of medicine in the Department of Family and Community Medicine, is one of many doctors on the forefront of changing the way medicine operates today, in the interest of optimizing its functionality and ability to heal people successfully. His book, *New Medicine*, not only is a road map for those interested in learning about integrative medicine but also is a blueprint for the medicine of the future. Read more

Arizona Daily Star

**UA Researcher Barnes Provides Insights into Aging, Memory**

After four decades of research, Carol Barnes, PhD, has become increasingly optimistic on the normal effects of aging on memory. A psychologist and neuroscientist who heads the University of Arizona’s Evelyn F. McKnight Brain Institute, Dr. Barnes offered some thoughts on aging in a recent interview. Dr. Barnes’ institute recently was awarded a $5 million matching grant by the McKnight Brain Research Foundation; earlier this month, Dr. Barnes received a Distinguished Scientific Contribution Award from the American Psychological Association. Read more
MedicalXpress.com

Curcumin Blocks the Metastasis of Colon Cancer by a Novel Mechanism

Novel research led by the University of Arizona Steele Children’s Research Center has identified one of the mechanisms by which curcumin, a bioactive molecule derived from the spice turmeric, can prevent cancer cell metastasis in colon cancer.

A team of researchers led by the UA’s Steele Children’s Research Center discovered that curcumin – the bioactive molecule derived from the spice turmeric – blocks the protein cortactin in colon cancer. Read more

KGUN9 (ABC-Tucson)

Local Doctors Testing New Drug to Treat Patients with Alzheimer’s Disease

The University of Arizona Medical Center is participating in a clinical trial to test a new drug for Alzheimer’s disease.

The drug, T-817MA, may be able to help patients with mild-to-moderate Alzheimer’s disease. No new drug has been approved by the U.S. Food and Drug Administration to help slow the progression of AD since 2003. The study by NOBLE could help patients who don’t respond well to the drugs already on the market. Read more

National Geographic

Ask Your Weird Animal Questions

This question came to us from an earlier column regarding which spider bites are most dangerous to humans.

Leslie Boyer, MD, of the University of Arizona, Tucson, says that “in most cases, the effects on bitten people are over within a matter of days, and the toxins are probably gone within a day or so after that.”
Once in a while an unlucky person is sick for a couple of weeks,” but that’s more the healing process than getting rid of the venom itself. Read more